Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
2045-2322
Extent
Online-Ressource
Language
Englisch
Notes
online resource.

Bibliographic citation
Placenta-specific1 (PLAC1) is a potential target for antibody-drug conjugate-based prostate cancer immunotherapy ; volume:7 ; number:1 ; day:17 ; month:10 ; year:2017 ; pages:1-13 ; date:12.2017
Scientific reports ; 7, Heft 1 (17.10.2017), 1-13, 12.2017

Creator
Nejadmoghaddam, Mohammad-Reza
Zarnani, Amir-Hassan
Ghahremanzadeh, Ramin
Ghods, Roya
Mahmoudian, Jafar
Yousefi, Maryam
Nazari, Mahboobeh
Ghahremani, Mohammad Hossein
Abolhasani, Maryam
Anissian, Ali
Mahmoudi, Morteza
Dinarvand, Rassoul
Contributor
SpringerLink (Online service)

DOI
10.1038/s41598-017-13682-9
URN
urn:nbn:de:101:1-2019102019501986166133
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:35 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Nejadmoghaddam, Mohammad-Reza
  • Zarnani, Amir-Hassan
  • Ghahremanzadeh, Ramin
  • Ghods, Roya
  • Mahmoudian, Jafar
  • Yousefi, Maryam
  • Nazari, Mahboobeh
  • Ghahremani, Mohammad Hossein
  • Abolhasani, Maryam
  • Anissian, Ali
  • Mahmoudi, Morteza
  • Dinarvand, Rassoul
  • SpringerLink (Online service)

Other Objects (12)

The First FDA-Approved Antibody-Drug Conjugate

The First FDA-Approved Antibody-Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Rovalpituzumab Tesirine: A Novel DLL3-Targeting Antibody–Drug Conjugate

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

An Antibody‐Drug Conjugate for Multiple Myeloma Prepared by Multi‐Arm Linkers

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

Co-administered antibody improves penetration of antibody–dye conjugate into human cancers with implications for antibody–drug conjugates

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Design considerations of an IL13Rα2 antibody–drug conjugate for diffuse intrinsic pontine glioma

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Developing an Antibody–Drug Conjugate Approach to Selective Inhibition of an Extracellular Protein

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate

Related objects